Loading…
Diagnosis, Treatment, and Follow-Up of Giant-Cell Arteritis: A Retrospective Multicenter Study
Giant-cell arteritis (GCA) is the most common type of vasculitis in the elderly and is associated with high risks of visual loss and recurrence. Owing to its rarity in Asian populations, the current clinical interventions for these patients are not well known. Here we aimed to characterize the curre...
Saved in:
Published in: | Journal of clinical neurology (Seoul, Korea) 2024, 20(3), , pp.306-314 |
---|---|
Main Authors: | , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | cdi_FETCH-LOGICAL-c379t-aedcf1d2b35f63e304f93e13f6e4f0cf101fd7d7b8f05e10b9bb91ad43499383 |
container_end_page | 314 |
container_issue | 3 |
container_start_page | 306 |
container_title | Journal of clinical neurology (Seoul, Korea) |
container_volume | 20 |
creator | Kang, Mi-Kyoung Hong, Yooha Kim, Yoo Hwan Park, Hong-Kyun Kim, Soo-Kyoung Sohn, Jong-Hee Kim, Jiyoung Kwon, Ki-Han Cho, Soo-Jin |
description | Giant-cell arteritis (GCA) is the most common type of vasculitis in the elderly and is associated with high risks of visual loss and recurrence. Owing to its rarity in Asian populations, the current clinical interventions for these patients are not well known. Here we aimed to characterize the current management status of patients with GCA using Korean multicenter data.
This retrospective study analyzed medical records of patients with GCA at six Korean university hospitals from February 2009 to November 2022. GCA had originally been diagnosed based on the 1990 American College of Rheumatology (ACR) criteria, and cases were selected for inclusion in this study based on the 2022 ACR/European Alliance of Associations for Rheumatology criteria. We evaluated treatments, follow-up periods, and outcomes (relapse, remission, and adverse drug reactions) in patients with GCA with or without arteritic anterior ischemic optic neuropathy (AAION).
This study analyzed 18 patients with a median age of 75.5 years that included 12 females (66.7%). Seven patients (38.8%) had AAION. All patients initially received prednisolone treatment, while four (22.2%) underwent adjuvant treatment with methotrexate and azathioprine during prednisolone tapering. During the median follow-up of 3.5 months (interquartile range: 2.0-23.2 months), 4 patients (22.2%) had prednisolone-related adverse reactions, 2 (11.1%) relapsed, and 13 (72.3%) dropped out. Nine patients (50.0%) experienced remission, with this being sustained in four (36.4%).
This study observed high dropout rates and short follow-ups. Adverse effects of prednisolone were common, and relapses occurred in approximately one-tenth of Korean patients with GCA. Thus, optimizing GCA treatment necessitates regular monitoring and long-term follow-up. |
doi_str_mv | 10.3988/jcn.2023.0169 |
format | article |
fullrecord | <record><control><sourceid>proquest_nrf_k</sourceid><recordid>TN_cdi_nrf_kci_oai_kci_go_kr_ARTI_10426795</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3040320895</sourcerecordid><originalsourceid>FETCH-LOGICAL-c379t-aedcf1d2b35f63e304f93e13f6e4f0cf101fd7d7b8f05e10b9bb91ad43499383</originalsourceid><addsrcrecordid>eNpVkUFP3DAQhS3UCraUI9fKxwqR7dhOHJsLWm0LRQIh0eWK5SQ2NWTjxXao-Pf17lJET3OYN-89zYfQIYEpk0J8e2iHKQXKpkC43EETClAVFRD2AU1IzUTBK8H30KcYHwB4DYLsoj0mOK0p5RN0993p-8FHF4_xIhidlmZIx1gPHT7zfe__FLcr7C0-d3pIxdz0PZ6FZIJLLp7gGb4xKfi4Mm1yzwZfjX1ybXYwAf9KY_fyGX20uo_m4HXuo8XZj8X8Z3F5fX4xn10WLatlKrTpWks62rDKcmYYlFYyQ5jlprSQV0BsV3d1IyxUhkAjm0YS3ZWslJIJto-OtrZDsOqxdcprt5n3Xj0GNbtZXCgCJeW1rLL4dCtejc0yB-e6QfdqFdxSh5fN6f-bwf3ORs-KEKg5ETw7fH11CP5pNDGppYtt_o0ejB-jyv2BURCbsGIrbfObYjD2LYeAWgNUGaBaA1RrgFn_5X25N_U_YuwvNd6Xhg</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3040320895</pqid></control><display><type>article</type><title>Diagnosis, Treatment, and Follow-Up of Giant-Cell Arteritis: A Retrospective Multicenter Study</title><source>PubMed Central</source><creator>Kang, Mi-Kyoung ; Hong, Yooha ; Kim, Yoo Hwan ; Park, Hong-Kyun ; Kim, Soo-Kyoung ; Sohn, Jong-Hee ; Kim, Jiyoung ; Kwon, Ki-Han ; Cho, Soo-Jin</creator><creatorcontrib>Kang, Mi-Kyoung ; Hong, Yooha ; Kim, Yoo Hwan ; Park, Hong-Kyun ; Kim, Soo-Kyoung ; Sohn, Jong-Hee ; Kim, Jiyoung ; Kwon, Ki-Han ; Cho, Soo-Jin</creatorcontrib><description>Giant-cell arteritis (GCA) is the most common type of vasculitis in the elderly and is associated with high risks of visual loss and recurrence. Owing to its rarity in Asian populations, the current clinical interventions for these patients are not well known. Here we aimed to characterize the current management status of patients with GCA using Korean multicenter data.
This retrospective study analyzed medical records of patients with GCA at six Korean university hospitals from February 2009 to November 2022. GCA had originally been diagnosed based on the 1990 American College of Rheumatology (ACR) criteria, and cases were selected for inclusion in this study based on the 2022 ACR/European Alliance of Associations for Rheumatology criteria. We evaluated treatments, follow-up periods, and outcomes (relapse, remission, and adverse drug reactions) in patients with GCA with or without arteritic anterior ischemic optic neuropathy (AAION).
This study analyzed 18 patients with a median age of 75.5 years that included 12 females (66.7%). Seven patients (38.8%) had AAION. All patients initially received prednisolone treatment, while four (22.2%) underwent adjuvant treatment with methotrexate and azathioprine during prednisolone tapering. During the median follow-up of 3.5 months (interquartile range: 2.0-23.2 months), 4 patients (22.2%) had prednisolone-related adverse reactions, 2 (11.1%) relapsed, and 13 (72.3%) dropped out. Nine patients (50.0%) experienced remission, with this being sustained in four (36.4%).
This study observed high dropout rates and short follow-ups. Adverse effects of prednisolone were common, and relapses occurred in approximately one-tenth of Korean patients with GCA. Thus, optimizing GCA treatment necessitates regular monitoring and long-term follow-up.</description><identifier>ISSN: 1738-6586</identifier><identifier>EISSN: 2005-5013</identifier><identifier>DOI: 10.3988/jcn.2023.0169</identifier><identifier>PMID: 38627226</identifier><language>eng</language><publisher>Korea (South): Korean Neurological Association</publisher><subject>Original ; 신경과학</subject><ispartof>Journal of Clinical Neurology, 2024, 20(3), , pp.306-314</ispartof><rights>Copyright © 2024 Korean Neurological Association.</rights><rights>Copyright © 2024 Korean Neurological Association 2024 Korean Neurological Association</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c379t-aedcf1d2b35f63e304f93e13f6e4f0cf101fd7d7b8f05e10b9bb91ad43499383</cites><orcidid>0000-0002-8693-2831 ; 0000-0001-6399-2236 ; 0000-0002-9532-5769 ; 0000-0002-8120-2469 ; 0000-0003-2656-9222 ; 0000-0001-7592-2921 ; 0000-0002-7230-4033 ; 0000-0002-4053-3763 ; 0000-0001-7260-3984</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11076186/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11076186/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38627226$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART003073222$$DAccess content in National Research Foundation of Korea (NRF)$$Hfree_for_read</backlink></links><search><creatorcontrib>Kang, Mi-Kyoung</creatorcontrib><creatorcontrib>Hong, Yooha</creatorcontrib><creatorcontrib>Kim, Yoo Hwan</creatorcontrib><creatorcontrib>Park, Hong-Kyun</creatorcontrib><creatorcontrib>Kim, Soo-Kyoung</creatorcontrib><creatorcontrib>Sohn, Jong-Hee</creatorcontrib><creatorcontrib>Kim, Jiyoung</creatorcontrib><creatorcontrib>Kwon, Ki-Han</creatorcontrib><creatorcontrib>Cho, Soo-Jin</creatorcontrib><title>Diagnosis, Treatment, and Follow-Up of Giant-Cell Arteritis: A Retrospective Multicenter Study</title><title>Journal of clinical neurology (Seoul, Korea)</title><addtitle>J Clin Neurol</addtitle><description>Giant-cell arteritis (GCA) is the most common type of vasculitis in the elderly and is associated with high risks of visual loss and recurrence. Owing to its rarity in Asian populations, the current clinical interventions for these patients are not well known. Here we aimed to characterize the current management status of patients with GCA using Korean multicenter data.
This retrospective study analyzed medical records of patients with GCA at six Korean university hospitals from February 2009 to November 2022. GCA had originally been diagnosed based on the 1990 American College of Rheumatology (ACR) criteria, and cases were selected for inclusion in this study based on the 2022 ACR/European Alliance of Associations for Rheumatology criteria. We evaluated treatments, follow-up periods, and outcomes (relapse, remission, and adverse drug reactions) in patients with GCA with or without arteritic anterior ischemic optic neuropathy (AAION).
This study analyzed 18 patients with a median age of 75.5 years that included 12 females (66.7%). Seven patients (38.8%) had AAION. All patients initially received prednisolone treatment, while four (22.2%) underwent adjuvant treatment with methotrexate and azathioprine during prednisolone tapering. During the median follow-up of 3.5 months (interquartile range: 2.0-23.2 months), 4 patients (22.2%) had prednisolone-related adverse reactions, 2 (11.1%) relapsed, and 13 (72.3%) dropped out. Nine patients (50.0%) experienced remission, with this being sustained in four (36.4%).
This study observed high dropout rates and short follow-ups. Adverse effects of prednisolone were common, and relapses occurred in approximately one-tenth of Korean patients with GCA. Thus, optimizing GCA treatment necessitates regular monitoring and long-term follow-up.</description><subject>Original</subject><subject>신경과학</subject><issn>1738-6586</issn><issn>2005-5013</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNpVkUFP3DAQhS3UCraUI9fKxwqR7dhOHJsLWm0LRQIh0eWK5SQ2NWTjxXao-Pf17lJET3OYN-89zYfQIYEpk0J8e2iHKQXKpkC43EETClAVFRD2AU1IzUTBK8H30KcYHwB4DYLsoj0mOK0p5RN0993p-8FHF4_xIhidlmZIx1gPHT7zfe__FLcr7C0-d3pIxdz0PZ6FZIJLLp7gGb4xKfi4Mm1yzwZfjX1ybXYwAf9KY_fyGX20uo_m4HXuo8XZj8X8Z3F5fX4xn10WLatlKrTpWks62rDKcmYYlFYyQ5jlprSQV0BsV3d1IyxUhkAjm0YS3ZWslJIJto-OtrZDsOqxdcprt5n3Xj0GNbtZXCgCJeW1rLL4dCtejc0yB-e6QfdqFdxSh5fN6f-bwf3ORs-KEKg5ETw7fH11CP5pNDGppYtt_o0ejB-jyv2BURCbsGIrbfObYjD2LYeAWgNUGaBaA1RrgFn_5X25N_U_YuwvNd6Xhg</recordid><startdate>20240501</startdate><enddate>20240501</enddate><creator>Kang, Mi-Kyoung</creator><creator>Hong, Yooha</creator><creator>Kim, Yoo Hwan</creator><creator>Park, Hong-Kyun</creator><creator>Kim, Soo-Kyoung</creator><creator>Sohn, Jong-Hee</creator><creator>Kim, Jiyoung</creator><creator>Kwon, Ki-Han</creator><creator>Cho, Soo-Jin</creator><general>Korean Neurological Association</general><general>대한신경과학회</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>ACYCR</scope><orcidid>https://orcid.org/0000-0002-8693-2831</orcidid><orcidid>https://orcid.org/0000-0001-6399-2236</orcidid><orcidid>https://orcid.org/0000-0002-9532-5769</orcidid><orcidid>https://orcid.org/0000-0002-8120-2469</orcidid><orcidid>https://orcid.org/0000-0003-2656-9222</orcidid><orcidid>https://orcid.org/0000-0001-7592-2921</orcidid><orcidid>https://orcid.org/0000-0002-7230-4033</orcidid><orcidid>https://orcid.org/0000-0002-4053-3763</orcidid><orcidid>https://orcid.org/0000-0001-7260-3984</orcidid></search><sort><creationdate>20240501</creationdate><title>Diagnosis, Treatment, and Follow-Up of Giant-Cell Arteritis: A Retrospective Multicenter Study</title><author>Kang, Mi-Kyoung ; Hong, Yooha ; Kim, Yoo Hwan ; Park, Hong-Kyun ; Kim, Soo-Kyoung ; Sohn, Jong-Hee ; Kim, Jiyoung ; Kwon, Ki-Han ; Cho, Soo-Jin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c379t-aedcf1d2b35f63e304f93e13f6e4f0cf101fd7d7b8f05e10b9bb91ad43499383</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Original</topic><topic>신경과학</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kang, Mi-Kyoung</creatorcontrib><creatorcontrib>Hong, Yooha</creatorcontrib><creatorcontrib>Kim, Yoo Hwan</creatorcontrib><creatorcontrib>Park, Hong-Kyun</creatorcontrib><creatorcontrib>Kim, Soo-Kyoung</creatorcontrib><creatorcontrib>Sohn, Jong-Hee</creatorcontrib><creatorcontrib>Kim, Jiyoung</creatorcontrib><creatorcontrib>Kwon, Ki-Han</creatorcontrib><creatorcontrib>Cho, Soo-Jin</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Korean Citation Index</collection><jtitle>Journal of clinical neurology (Seoul, Korea)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kang, Mi-Kyoung</au><au>Hong, Yooha</au><au>Kim, Yoo Hwan</au><au>Park, Hong-Kyun</au><au>Kim, Soo-Kyoung</au><au>Sohn, Jong-Hee</au><au>Kim, Jiyoung</au><au>Kwon, Ki-Han</au><au>Cho, Soo-Jin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Diagnosis, Treatment, and Follow-Up of Giant-Cell Arteritis: A Retrospective Multicenter Study</atitle><jtitle>Journal of clinical neurology (Seoul, Korea)</jtitle><addtitle>J Clin Neurol</addtitle><date>2024-05-01</date><risdate>2024</risdate><volume>20</volume><issue>3</issue><spage>306</spage><epage>314</epage><pages>306-314</pages><issn>1738-6586</issn><eissn>2005-5013</eissn><abstract>Giant-cell arteritis (GCA) is the most common type of vasculitis in the elderly and is associated with high risks of visual loss and recurrence. Owing to its rarity in Asian populations, the current clinical interventions for these patients are not well known. Here we aimed to characterize the current management status of patients with GCA using Korean multicenter data.
This retrospective study analyzed medical records of patients with GCA at six Korean university hospitals from February 2009 to November 2022. GCA had originally been diagnosed based on the 1990 American College of Rheumatology (ACR) criteria, and cases were selected for inclusion in this study based on the 2022 ACR/European Alliance of Associations for Rheumatology criteria. We evaluated treatments, follow-up periods, and outcomes (relapse, remission, and adverse drug reactions) in patients with GCA with or without arteritic anterior ischemic optic neuropathy (AAION).
This study analyzed 18 patients with a median age of 75.5 years that included 12 females (66.7%). Seven patients (38.8%) had AAION. All patients initially received prednisolone treatment, while four (22.2%) underwent adjuvant treatment with methotrexate and azathioprine during prednisolone tapering. During the median follow-up of 3.5 months (interquartile range: 2.0-23.2 months), 4 patients (22.2%) had prednisolone-related adverse reactions, 2 (11.1%) relapsed, and 13 (72.3%) dropped out. Nine patients (50.0%) experienced remission, with this being sustained in four (36.4%).
This study observed high dropout rates and short follow-ups. Adverse effects of prednisolone were common, and relapses occurred in approximately one-tenth of Korean patients with GCA. Thus, optimizing GCA treatment necessitates regular monitoring and long-term follow-up.</abstract><cop>Korea (South)</cop><pub>Korean Neurological Association</pub><pmid>38627226</pmid><doi>10.3988/jcn.2023.0169</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-8693-2831</orcidid><orcidid>https://orcid.org/0000-0001-6399-2236</orcidid><orcidid>https://orcid.org/0000-0002-9532-5769</orcidid><orcidid>https://orcid.org/0000-0002-8120-2469</orcidid><orcidid>https://orcid.org/0000-0003-2656-9222</orcidid><orcidid>https://orcid.org/0000-0001-7592-2921</orcidid><orcidid>https://orcid.org/0000-0002-7230-4033</orcidid><orcidid>https://orcid.org/0000-0002-4053-3763</orcidid><orcidid>https://orcid.org/0000-0001-7260-3984</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1738-6586 |
ispartof | Journal of Clinical Neurology, 2024, 20(3), , pp.306-314 |
issn | 1738-6586 2005-5013 |
language | eng |
recordid | cdi_nrf_kci_oai_kci_go_kr_ARTI_10426795 |
source | PubMed Central |
subjects | Original 신경과학 |
title | Diagnosis, Treatment, and Follow-Up of Giant-Cell Arteritis: A Retrospective Multicenter Study |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T22%3A18%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_nrf_k&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Diagnosis,%20Treatment,%20and%20Follow-Up%20of%20Giant-Cell%20Arteritis:%20A%20Retrospective%20Multicenter%20Study&rft.jtitle=Journal%20of%20clinical%20neurology%20(Seoul,%20Korea)&rft.au=Kang,%20Mi-Kyoung&rft.date=2024-05-01&rft.volume=20&rft.issue=3&rft.spage=306&rft.epage=314&rft.pages=306-314&rft.issn=1738-6586&rft.eissn=2005-5013&rft_id=info:doi/10.3988/jcn.2023.0169&rft_dat=%3Cproquest_nrf_k%3E3040320895%3C/proquest_nrf_k%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c379t-aedcf1d2b35f63e304f93e13f6e4f0cf101fd7d7b8f05e10b9bb91ad43499383%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3040320895&rft_id=info:pmid/38627226&rfr_iscdi=true |